Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

3D Medicines, Inc. (1244) Stock Price & Analysis

1244 Stock Chart & Stats

HK$2.61HK$0.10(3.98%)
At close: 4:00 PM GMT+8
HK$2HK$2.5HK$33 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
HKD 2.50 - HKD 2.62
52-Week Range
HKD 1.82 - HKD 6.42
Previous Close
HKD 2.51
Volume
120.00K
Average Volume (3M)
38.25K
Market Cap
HKD 673.84M
Enterprise Value
HKD 471.71M
Total Cash (Recent Filing)
HKD 394.59M
Total Debt (Recent Filing)
HKD 171.36M
Price to Earnings (P/E)
―
Beta
0.61
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High Gross Margin

A gross margin of roughly 92% indicates strong economics on the revenue already generated. If sustained, this can provide substantial capacity to support oncology research, development, and commercialization, although operating expenses currently prevent the margin from translating into profitability.

Narrowing Losses

Substantially narrower losses versus 2022–2023 suggest that cost discipline and/or improving product mix is having a meaningful effect. Continued progress could move the company toward break-even over time, even though sustained bottom-line profitability has not yet been demonstrated.

Manageable Leverage

A debt-to-equity ratio near 0.26 indicates the company is not heavily debt-funded today, while the improvement from prior years reduces balance-sheet pressure. This gives management greater flexibility to fund operations and development without excessive leverage, subject to ongoing losses.

Bears Say

Revenue Contraction

A roughly 23% year-over-year revenue decline weakens operating leverage and indicates that commercial growth has not yet become dependable. Continued contraction would make it harder to absorb fixed research, development, and commercial costs, delaying the path to sustainable profitability.

Persistent Net Losses

Large ongoing net losses show that the company’s strong gross margin is currently insufficient to cover operating and other expenses. Persistent losses can consume capital over time and leave the business dependent on future improvement in revenue, costs, or financing to reach sustainability.

Negative Cash Generation

Negative operating and free cash flow demonstrate that the company is still consuming cash to fund its operations rather than internally financing growth. If this burn persists, reliance on financing may increase and could constrain investment in the oncology pipeline or commercial expansion.

3D Medicines, Inc. News

1244 FAQ

What was 3D Medicines, Inc.’s price range in the past 12 months?
3D Medicines, Inc. lowest stock price was HK$1.82 and its highest was HK$6.42 in the past 12 months.
What is 3D Medicines, Inc.’s market cap?
3D Medicines, Inc.’s market cap is HK$673.84M.
When is 3D Medicines, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 3D Medicines, Inc.’s earnings last quarter?
3D Medicines, Inc. released its earnings results on Aug 31, 2026. The company reported -HK$0.395 earnings per share for the quarter.
Is 3D Medicines, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does 3D Medicines, Inc. pay dividends?
3D Medicines, Inc. does not currently pay dividends.
What is 3D Medicines, Inc.’s EPS estimate?
3D Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3D Medicines, Inc. have?
3D Medicines, Inc. has 258,177,000 shares outstanding.
What happened to 3D Medicines, Inc.’s price movement after its last earnings report?
3D Medicines, Inc. reported an EPS of -HK$0.395 in its last earnings report. Following the earnings report the stock price went down -4.432%.
Which hedge fund is a major shareholder of 3D Medicines, Inc.?
Currently, no hedge funds are holding shares in HK:1244
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology